Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools

Tissue Engineering

Volumn 13, Issue 10, 2007, Pages 2561-2575

  Wieghaus, Kristen A ^a   Gianchandani, Erwin P ^a   Brown, Milton L ^b   Papin, Jason A ^a,c   Botchwey, Edward A ^a,c  

^a University of Virginia   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MECHANISTIC EXPLORATION; NEOVASCULARIZATION; NETWORK ANALYSIS TOOLS; PHTHALIMIDE NEOVASCULAR FACTORS;

AMIDES; BIOACTIVITY; BIOMOLECULES; ENDOTHELIAL CELLS; NUCLEIC ACIDS; TRANSCRIPTION;

TISSUE ENGINEERING;

COMPLEMENTARY DNA; ENDOGLIN; EPHRIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; GLUCAN SYNTHASE; PHTHALIMIDE NEOVASCULAR FACTOR 1; PLASMINOGEN; RAS PROTEIN; RHO FACTOR; THROMBOSPONDIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL FUNCTION; CELL SURVIVAL; DNA MICROARRAY; ENDOTHELIUM CELL; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMPLANTATION; IN VIVO STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

ANGIOGENIC PROTEINS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; SOFTWARE;

EID: 35348903141     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2007.0023     Document Type: Article

References (98)

1. Brey, E.M., Uriel, S., Greisler, H.P., Patrick Jr., C.W., and McIntire, L.V. Therapeutic neovascularization: contributions from bioengineering. Tissue Eng 11, 567, 2005.
2. Madeddu, P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 90, 3154, 2005.
3. Levenberg, S., Rouwkema, J., Macdonald, M., Garfein, E.S., Kohane, D.S., Darland, D.C., Marini, R., van Blitterswijk, C.A., Mulligan, R.C., D'Amore, P.A., and Langer, R. Engineering vascularized skeletal muscle tissue. Nat Biotechnol 23, 879, 2005.
4. Li, W.W., Talcott, K.E., Zhai, A.W., Kruger, E.A., and Li, V.W. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care 18, 491, 2005.
5. Cassell, O.C.S., Hofer, S.O.P., Morrison, W.A., and Knight, K.R. Vascularization of tissue-engineered grafts: the regulation of angiogenesis in reconstructive surgery and in disease states. Br J Plast Surg 55, 603, 2002.
6. Hockel, M., Schlenger, K., Doctrow, S., Kissel, T., and Vaupel, P. Therapeutic angiogenesis. Arch Surgery 128, 423, 1993.
7. Berglund, J.D., and Galis, Z.S. Designer blood vessels and therapeutic revascularization. Br J Pharmacol 140, 627, 2003.
8. Bernas, G.C. Angiotherapeutics from natural products: from bench to clinics? Clin Hemorheol Microcirc 29, 199, 2003.
9. Freedman, S.B., and Isner, J.M. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 136, 54, 2002.
10. Hughes, G.C., Biswas, S.S., Tin, B., Coleman, R.E., DeGrado, T.R., Landolfo, C.K., Lowe, J.E., Annex, B.H., and Landolfo, K.P. Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thorac Surg 77, 812, 2004.
11. Lei, Y., Haider, H.K., Shujia, J., and Sim, E.S.K. Therapeutic angiogenesis: devising new strategies based on past experiences. Basic Res Cardiol 99, 121, 2004.
12. Henry, T.D., Annex, B.H., McKendall, G.R., Azrin, M.A., Lopez, J.J., Giordano, F.J., Shah, P.K., Willerson, J.T., Benza, R.L., Berman, D.S., Gibson, C.M., Bajamonde, A., Rundle, A.C., Fine, J., and McCluskey, E.R. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107, 1359, 2003.
13. Simons, M., Annex, B.H., Laham, R.J., Kleiman, N., Henry, T., Dauerman, H., Udelson, J.E., Gervino, E.V., Pike, M., Whitehouse, M.J., Moon, T., and Chronos, N.A. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788, 2002.
14. Barnard, G.C., McCool, J.D., Wood, D.W., and Gerngross, T.U. Integrated recombinant protein expression and purification platform based on ralstonia eutropha. Appl Environ Microbiol 71, 5735, 2005.
15. Chi, E.Y., Krishnan, S., Randolph, T.W., and Carpenter, J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20, 1325, 2003.
16. Cryan, S-A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 7, E20, 2005.
17. Baklanov, D., and Simons, M. Arteriogenesis: lessons learned from clinical trials. Endothelium 10, 217, 2003.
18. Wacker, B.K., Scott, E.A., Kaneda, M.M., Alford, S.K., Elbert, D.L. Delivery of sphingosine 1-phosphate from poly(ethylene glycol) hydrogels. Biomacromolecules 7, 1335, 2006.
19. Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.X., Hobson, J.P., Rosenfeldt, H.M., Nava, V.E., Chae, S.S., Lee, M.J., Liu, C.H., Hla, T., Spiegel, S., and Proia, R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106, 951, 2000.
20. Kona, M., Mi, Y., Liu, Y., Sasaki, T., Allende, M.L., Wu, Y-P., Yamashita, T., and Proia, R.L. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 279, 29367, 2004.
21. Milkiewicz, M., Pugh, C.W., and Egginton, S. Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol 560, 21, 2004.
22. Nagle, D.G., and Zhou, Y-D. Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1). Curr Pharm Des 12, 2673, 2006.
23. Wieghaus, K.A., Capitosti, S.M., Anderson, C.R., Blackman, B.R., Price, R.J., Brown, M.L., and Botchwey, E.A. Small molecule inducers of angiogenesis for tissue engineering. Tissue Eng 12, 1903, 2006.
24. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J-P., Subramanian, A., Ross, K.N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S.A., Haggarty, S.J., Clemons, P.A., Wei, R., Carr, S.A., Lander, E.S., and Golub, T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929, 2006.
25. Crawford, F.C., Wood, M.L., Wilson, S.E., Mathura, V.S., Hollen, T.R., Geall, F., Kolippakkam, D.N., and Mullan, M.J. Cocaine induced inflammatory response in human neuronal progenitor cells. J Neurochem 97, 662, 2006.
26. Kim, Y., Ton, T-V., DeAngelo, A.B., Morgan, K., Devereux, T.R., Anna, C., Collins, J.B., Paules, R.S., Crosby, L.M., and Sills, R.C. Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats. Toxicol Appl Pharm 214, 144, 2006.
27. Mayburd, A.L., Martinez, A., Sackett, D., Liu, H., Shih, J., Tauler, J., Avis, I., and Sulsine, J.L. Ingenuity network-assisted transcription profiling: identification of a new pharmacologic mechanism for MK886. Clinical Cancer Res 12, 1820, 2006.
28. Raponi, M., Belly, R.T., Karp, J.E., Lancet, J.E., Atkins, D., and Wang, Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4, 56, 2004.
29. Liu, J., Xie, Y., Ducharme, D.M.K., Shen, J., Diwan, B.A., Merrick, B.A., Grissom, S.F., Tucker, C.J., Paules, R.S., Tennant, R., and Waalkes, M.P. Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. 114, 404, 2006.
30. Higo, M., Uzaka, K., Kawata, T., Kato, Y., Kouzu, Y., Yamamoto, N., Shibahara, T., Mizoe, J-E., Ito, H., Tsujii, H., and Tanzawa, H. Enhancement of SPHK1 in vitro by carbon ion irradiation in oral squamous cell carcinoma. Int J Radiation Oncology Biol Phys 65, 867, 2006.
31. Kasamatsu, A., Endo, Y., Uzawa, K., Nakashima, D., Koike, H., Hashitani, S., Numata, T., Urade, M., and Tanzawa. Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses. Int J Biochem Cell Biol 37, 1869, 2005.
32. Solini, A., Santini, E., Nannipieri, M., and Ferrannini, E. High glucose and homocysteine synergistically affect the metalloproteinases - tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia 49, 2499, 2006.
33. Lux, A., Salway, F., Dressman, H.K., Kroner-Lux, G., Hafner, M., Day, P.J.R., Marchuk, D.A., and Garland, J. ALK1 signaling analysis identifies angiogenesis related genes and reveals disparity between TGF-β and constitutively active receptor induced gene expression. BMC Cardiovascular Disorders 6, 13, 2006.
34. Soufla, G., Sifakis, S., Baritaki, S., Zafiropoulos, A., Koumantakis, E., and Spandidos, D.A. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 221, 105, 2005.
35. Bock, O., Yu, H., Zitron, S., Bayat, A., Ferguson, M.W.J., and Mrowietz, U. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta Derm Venereol 85, 216, 2005.
36. Jones, R.L., Salamonsen, L.A., Zhao, Y.C., Ethier, J-F., Drummond, A.E., and Findlay, J.K. Expression of activin receptors, follistatin, and betaglycan by human endometrial stromal cells; consistent with a role for activins during decidualization. Mol Hum Reprod 8, 363, 2002.
37. Li, D., Chen, H., and Mehta, J.L. Angiotensin II via activation of type I receptor upregulates expression of endoglin in human coronary artery endothelial cells. Hypertension 38, 062, 2001.
38. Uray, I.P., Liang, Y., and Hyder, S.M. Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Lett 207, 101, 2004.
39. Zeng, Q., Smith, D.C., Suscovich, T.J., Gooding, W.E., Trump, D.L., and Grandis, J.R. Determination of intermediate biomarker expression levels by quantitative reverse-transcriptase polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res. 6, 2245, 2006.
40. Hossain, M.A., Fielding, K.E., Trescher, W.H., Ho, T., Wilson, M.A., and Laterra, J. Human FGF-1 gene delivery protects against quinolinate-induced striatal and hippocampal injury in neonatal rats. Euro J Neurosci 10, 2490, 1998.
41. Frank, O., Heim, M., Jakob, M., Barbero, A., Schafer, D., Bendik, I., Dick, W., Heberer, M., and Martin, I. Real-time quantitative RT-PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro. J Cell Biochem 85, 737, 2002.
42. Delafontaine, P., Song, Y-H., and Li, Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24, 435, 2004.
43. Nakao-Hayashi, J., Ito, H., Kanayasu, T., Morita, I., and Murota, S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis. 92, 141, 1992.
44. Tucci, M., Nygard, K., Tanswell, B.V., Farber, H.W., Hill, D.J., and Han, V.K. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. J Endocrinol. 157, 13, 1998.
45. Galaup, A., Cazes, A., Le Jan, S., Philippe, J., Connault, E., Le Coz, E., Mekid, H., Mir, L.M., Opolon, P., Corvol, P., Monnot, C., and Germain, S. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. Epub ahead of print, 2006.
46. Le Jan, S., Amy, C., Cazes, A., Monnot, C., Lamande, N., Favier, J., Philippe, J., Sibony, M., Gasc, J.M., Corvol, P., and Germain, S. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 162, 1521, 2003.
47. Azhar, M., Schultz, J.O., Grupp, I., Dorn II, G.W., Meneton, P., Molin, D.G.M., Gittenberger-de Groot, A.C., and Doetschman, T. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 14, 391, 2003.
48. Marchuk, D.A., Srinvasian, S., Squire, T.L., and Zawistowski, J.S. Vascular morphogenesis: tales of two syndromes. Hum Mol Genet 12, R97, 2003.
49. Pepper, M.S. Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8, 21, 1997.
50. Heldin, C-H., Miyazono, K., and ten Dijke, P. TGF-b signaling from cell membrane to nucleus through SMAD proteins. Nature 390, 465, 1997.
51. Shi, Y., and Massague, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685, 2003.
52. Massague, J., and Chen, Y.G. Controlling TGF-beta signaling. Genes Dev 14, 627, 2000.
53. Wrana, J.L. TGF-beta receptors and signaling mechanisms. Miner Electrolyte Metab 24, 120, 1998.
54. Wang, X.F., Lin, H.Y., Ng-Eaton, E., Downward, J., Lodish, H.F., and Weinberg, RA. Expression cloning and characterization of the TGF-beta type III receptor. Cell 67, 797, 1001.
55. Cheifetz, S., Bellon, T., Cales, C., Vera, S., Bernabeu, C., Massague, J., and Letarte, M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267, 19027, 1992.
56. Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J.L., Lane, W.S., and Massague, J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67, 785, 1991.
57. Han, J., Hajjar, D.P., Tauras, J.M., Feng, J., Gotto Jr., A.M. and Nicholson, A.C. Transforming growth factor-β1 (TGFβ-1) and TGFβ-2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ. J Biol Chem 275, 1241, 2000.
58. Primo, L., Ferrandi, C., Roca, C., Marchio, S., di Blasio, L., Alessio, M., and Bussolino, F. Identification of CD36 molecular features required for its angiostatic activity. FASEB J 19, 1713, 2005.
59. Dawson, D.W., Pearce, S.F., Zhong, R., Silverstein, R.L., Frazier, W.A., and Bouck, N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138, 707, 1997.
60. Febbraio, M., Hajjar, D.P., and Silverstein, R.L. (2001) "CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism." J Clin Invest 108, 785, 2001.
61. Jimenez, B., Volpert, O.V., Crawford, S.E., Febbraio, M., Silverstein, R.L., and Bouck, N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6, 41, 2000.
62. Wang, S., Hasham, M.G., Isordia-Salas, I., Tsygankov, A.Y., Colman, R.W., and Guo, Y.L. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am J Physiol Heart Circ Physiol 284, H1917, 2003.
63. Choi, K.S., Eom, Y.W., Kang, Y., Ha, M.J., Rhee, H., Yoon, J.W., and Kim, S.J. Cdc2 and Cdc2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. J Biol Chem 274, 31775, 1999.
64. Skjerpen, C.S., Wesche, J., and Olsnes, S. Identification of ribosome-binding protein p34 as an intracellular protein that binds acidic fibroblast growth factor. J Biol Chem 277, 23864, 2002.
65. Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., and Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16, 159, 2005.
66. Vardouli, L., Moustakas, A., and Stournaras, C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-β. J Biol Chem 280, 11448, 2005.
67. Chambers, R.C., Leoni, P., Kaminski, N., Laurent, G.J., and Heller, R.A. Global expression profiling of fibroblast responses to transforming growth factor-β(1) reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162, 533, 2003.
68. Adini, I., Rabinovitz, I., Sun, J.F., Prendergast, G.C., and Benjamin, L.E. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev 17, 2721, 2003.
69. Murillo, M.M., Castillo, G.D., Sánchez, A., Fernández, M., and Fabregat, I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 24, 4580, 2005.
70. Viñals, F., and Pouysségur, J. Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol 21, 7218, 2001.
71. Hirata, A., Ogawa, S., Kometani, T., Kuwano, T., Naito, S., Kuwano, M., and Ono, M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62, 2554, 2002.
72. Suhardja, A., and Hoffman, H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech 60, 70, 2003.
73. Zou, J.X., Wang, B., Kalo, M.S., Zisch, A.H., Pasquale, E.B., and Ruoslahti, E. An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci USA 96, 13813, 1999.
74. Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., and Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 407, 242, 2000.
75. Adams, R.H., Wilkinson, G.A., Weiss, C., Diella, F., Gale, N.W., Deutsch, U., Risau, W., and Klein, R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Gene Dev 13, 295, 1999.
76. Zavadil, J., Cermak, L., Soto-Nieves, N., and Böttinger, E.P. Integration of TGF-beta/Smad and Jagged1/Notch signaling in epithelial-to- mesenchymal transition. EMBO J 23, 1155, 2004.
77. Tsunematsu, R., Nakayama, K., Oike, Y., Nishiyama, M., Ishida, N., Hatakeyama, S., Bessho, Y., Kageyama, R., Suda, T., and Nakayama, K.I. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Cell 279, 9417, 2004.
78. Pellacani, A., Wiesel, P., Razavi, S., Vasilj, V., Feinberg, M.W., Chin, M.T., Reeves, R., and Perrella, M.A. Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor-beta1. J Biol Chem 276, 1653, 2001.
79. Pierantoni, G.M., Rinaldo, C., Esposito, F., Mottolese, M., Soddu, S., and Fusco, A. High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ Epub ahead of print, 2005.
80. Cooke, J.P. NO and angiogenesis. Atheroscel Supp 4, 53, 2003.
81. Huang, Y., Shi, H., Zhou, H., Song, X., Yuan, S., and Luo, Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107, 3564, 2006.
82. Santibáñez, J.F., Quintanilla, M., and Martínez, J. Genistein and curcumin block TGF-beta 1-induced u-PA expression and migratory and invasive phenotype in mouse epidermal keratinocytes. Nutr Cancer 37, 49, 2000.
83. Novokhatny, V., Medved, L., Lijnen, H.R., and Ingham, K. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules. J Biol Chem 270, 8680, 1995.
84. van Hinsbergh, V.W., Koolwijk, P., and Hanemaaijer, R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 79, 391, 1997.
85. Mignatt, P., and Rifkin, D.B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49, 117, 1996.
86. Carmeliet, P., and Collen, D. Molecular analysis of blood vessel formation and disease. Am J Physiol. 273, H2091, 1997.
87. Lalioti, V.S., Vergarajauregui, S., Pulido, D., and Sandoval, I.V. The insulin-sensitive glucose transporter, GLUT4, interacts physically with Daxx. Two proteins with capacity to bind Ubc9 and conjugated to SUMO1. J Biol Chem 277, 19783, 2002.
88. Lin, H.K., Bergmann, S., and Pandolfi, P.P. Cytoplasmic PML function in TGF-beta signaling. Nature 431, 205, 2004.
89. Wu, F., Buckley, S., Bui, K.C., Yee, A., Wu, H.Y., Liu, J., and Warburton, D. Cell cycle arrest in G0/G1 phase by contact inhibition and TGF-beta 1 in mink Mv1Lu lung epithelial cells. Am J Physiol 270, L879, 1996.
90. Yang, Y.L., Guh J.Y., Yang, M.L., Lai, Y.H., Tsai, J.H., Hung, W.C., Chang, C.C., and Chuang, L.Y. Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells. J Am Soc Nephrol 9, 182, 1998.
91. Karlsson, G., Liu, Y., Larsson, J., Goumans, M.J., Lee, J.S., Thorgeirsson, S.S., Ringner, M., and Karlsson, S. Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling. Physiol Genomics 21, 396, 2005.
92. Morgan, T.E., Rozovsky, I., Sarkar, D.K., Young-Chan, C.S., Nichols, N.R., Laping, N.J., and Finch, C.E. Transforming growth factor-beta 1 induces transforming growth factor-beta 1 and transforming growth factor-beta receptor messenger RNAs and reduces complement C1qB messenger RNA in rat brain microglia. Neuroscience 101, 313, 2000.
93. Brekken, R.A., Li, C., and Kumar, S. Strategies for vascular targeting in tumours. Int J Cancer 100, 123, 2002.
94. Sanchez-Elsner, T., Botella, L.M., Velasco, B., Langa, C., and Bernabeu, C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277, 43799, 2002.
95. Lebrin, F., Goumans, M-J., Jonker, L., Carvalho, R.L.C., Valdimarsdottir, G., Thorikay, M., Mummery, C., Arthur, H.M., and ten Dijke, P. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 23, 4018, 2004.
96. Bandyopadhyay, A., Zhu, Y., Malik, S.N., Kreisberg, J., Brattain, M.G., Sprague, E.A., Luo, J., Lopez-Casillas, F., and Sun, L.Z. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21, 3541, 2002.
97. Wong, S.H., Hamel, L., Chevalier, S., and Philip, A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem 267, 5550, 2000.
98. Goumans, M.J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery, C., Karlsson, S., and ten Dijke, P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of later TGFβ/ALK5 signaling. Mol Cell 12, 817, 2003.